Lung cancer. 9: Molecular biology of lung cancer: clinical implications

Fong K M; Sekido Y; Gazdar A F; Minna J D; Fong, K M; Sekido, Y; Gazdar, A F; Minna, J D
October 2003
Thorax;Oct2003, Vol. 58 Issue 10, p892
Academic Journal
journal article
It has been hypothesised that clinically evident lung cancers have accumulated many different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes. This notion has important clinical ramifications. Recent developments in our knowledge of the molecular biology of lung cancer are reviewed, with particular reference to genetic abnormalities in tumour suppressor gene inactivation and overactivity of growth promoting oncogenes. These changes lead to the "hallmarks of lung cancer". These hallmarks are the new rational targets for early detection, prevention, and treatment of lung cancer.


Related Articles

  • The non-coding RNAs of the H19-IGF2 imprinted loci: A focus on biological roles and therapeutic potential in Lung Cancer. Matouk, Imad J.; Halle, David; Gilon, Michal; Hochberg, Abraham // Journal of Translational Medicine;2015, Vol. 13 Issue 1, p1 

    Since it was first described, the imprinted cluster 11p15.5 has been reported to be deregulated in a variety of pediatric and adult cancers including that of the lung. Both protein coding and non-coding genes functioning as oncogenes or as tumor suppressor genes reside within this cluster....

  • Cancer epigenetics: Dangerous unmarked genes. Goymer, Patrick // Nature Reviews Genetics;Dec2005, Vol. 6 Issue 12, p878 

    The article provides information on a study by Rudolf Jaenisch and colleagues, which have demonstrated that global loss of imprinting leads to tumor formation. In the study, the researchers found that imprinting is an epigenetic tumor-suppressing phenomenon. When imprinting is lost, cells are...

  • Identification of DOK genes as lung tumor suppressors. Berger, Alice H.; Niki, Masaru; Morotti, Alessandro; Taylor, Barry S.; Socci, Nicholas D.; Viale, Agnes; Brennan, Cameron; Szoke, Janos; Motoi, Noriko; Rothman, Paul B.; Teruya-Feldstein, Julie; Gerald, William L.; Ladanyi, Marc; Pandolfi, Pier Paolo // Nature Genetics;Mar2010, Vol. 42 Issue 3, p216 

    Genome-wide analyses of human lung adenocarcinoma have identified regions of consistent copy-number gain or loss, but in many cases the oncogenes and tumor suppressors presumed to reside in these loci remain to be determined. Here we identify the downstream of tyrosine kinase (Dok) family...

  • Alterations in the K-ras and p53 genes in rat lung tumors. Belinsky, Steven A.; Swafford, Deborah S. // Environmental Health Perspectives Supplements;Jun97 Supplement 4, Vol. 105, p901 

    focuses on investigations into the role of the K-ras protooncogene and p53 tumor suppressor genes in lung tumors induced in rats by mutagenic and nonmutagenic exposures. Exposure and sampling; Mutations in the K-ras gene; Mutations in the p53 gene.

  • Tumor suppressor TSLC1 inhibits growth, proliferation, invasiveness and angiogenesis in nude mice xenografted tumor of Eca109 cells. Qi-Lian Liang; Guo-Qiang Chen; Qiu-Long Liu; Zhou-Yu Li; Xiang-Ning Zhang; Yuan Zhou; Wen-Ting Ou; Bi-Rong Wang; Li-Ren Hu // International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 6, p1507 

    Tumor suppressor in lung cancer 1 (TSLC1) is a novel tumor suppressor gene whose inactivation is implicated in the occurrence, invasion, metastasis and prognosis of esophageal cancer. TSLC1 was studied by comparing the tumor formation of TSLC1 transfectant and control cells in nude mice....

  • Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Jian Gu; Lidong Zhang; Bingliang Fang; Swisher, Stephen G.; Liu, Jinsong; Roth, Jack A. // Oncogene;2/12/2004, Vol. 23 Issue 6, p1300 

    The p53 gene is the most frequently mutated gene in human cancers. Loss of functional p53 leads to impaired responses of cancer cells to apoptosis induction and to poor prognosis in patients with certain types of cancer. Cancer gene therapies using ectopic expression of wild-type p53 to force...

  • EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Okamoto, J; Hirata, T; Chen, Z; Zhou, H-M; Mikami, I; Li, H; Yagui-Beltran, A; Johansson, M; Coussens, L M; Clement, G; Shi, Y; Zhang, F; Koizumi, K; Shimizu, K; Jablons, D; He, B // Oncogene;11/4/2010, Vol. 29 Issue 44, p5976 

    No abstract available.

  • Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy. Qi Zhao Wang; William Xu; Nagy Habib; Ruian Xu // Current Cancer Drug Targets;Jun2009, Vol. 9 Issue 4, p572 

    Lung cancer is the leading cause of death from cancer in the world. Although the molecular network of lung carcinogenesis has been partly known at the levels of genes and proteins, and personalized therapy based on the genetic changes has made considerable progress in the last decade, the high...

  • The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Lee, S-O; Andey, T; Jin, U-H; Kim, K; Singh, M; Safe, S // Oncogene;7/5/2012, Vol. 31 Issue 27, p3310 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics